Linköping, Stockholm, Uppsala
over 18 years
Healthy individuals, Patient studiesStudy 1027
We are looking for women who have an ongoing yeast infection in the genital area for a research study.
The study uses a vaginal tablet that is approved for the treatment of another genital infection and contains a substance that occurs naturally in the body. The purpose of the study is to evaluate whether the treatment has an effect on symptoms and signs of yeast infection in the genital area after 6 days of treatment compared to no treatment.
Candidal vulvovaginitis (yeast infection in the genital area) is a common infection in the genital area, with the most common symptoms being itching and/or burning. There are already several approved drugs for candidal vulvovaginitis, but there is a need for new, safe, over-the-counter alternatives where resistance development is not a risk.
Target group: women over the age of 18 with an ongoing yeast infection in the genital area
Criteria for participation:
- Have symptoms and signs of candidal vulvovaginitis
- Be at least 18 years old and have started menstruating
- Not yet entered menopause
- Not be pregnant or breastfeeding
- Not treated for fungal infection in the last two weeks
- Have no other confirmed or suspected vaginal infection
- Not having participated in another drug study in the past month
- Be willing to use contraception during your studies
Participants will be randomly divided into two groups, a larger group that will receive treatment with vaginal tablets and a smaller group that will receive no treatment at all for seven days.
For the group receiving treatment with vaginal tablets, the study consists of three visits to the clinic and a follow-up phone call over a total period of 25–28 days. During your first visit, you will receive vaginal tablets to use at home in the evening before going to bed for a 6-day treatment, and during your second visit (days 7–9), you will receive vaginal tablets for an additional 6 days of treatment.
For the group that does not receive treatment, the study consists of two visits to the clinic. The second visit takes place 7–9 days after the first. At this visit, all participants who need a single dose of fluconazole for their candidal vulvovaginitis receive it.
Compensation
You will receive compensation (max. SEK 3,300) for your participation as well as travel expenses.
Available times
| Linköping | Available times each week |
| Stockholm | Available times each week |
| Uppsala | Available times each week |
Fill out the form below and we will contact you to book a time that suits you.
More information and registration
Would you like to participate in the study? Submit an expression of interest using the form below.
Do you have questions or want to know more? Call 018-30 33 99 or email info@ctc-ab.se.
The study has been approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. Your participation is voluntary, and you may withdraw at any time. The information you provide will be processed in accordance with the General Data Protection Regulation (GDPR).
